ERBB3 and breast carcinoma: In patients diagnosed with estrogen receptor (ER)-positive breast cancer, erbB3 upregulation occurs after treatment with fulvestrant, activating the MAPK/ERK pathway and leading to resistance to antiestrogen therapy [34].